Home   Bookmark and Share
Choose language  
Get the latest info about new FDA drugs medication, side affects, dosage, generic alternative and treatment, prices, sample tablets availiblity and prescription details with news and forum. What is ...? Where can I find, How to buy….? What are side Effects of …. How do I take….Tablet, Pill, Liquid or Capsule, Get it all at DrugsReport.co.uk
Drug Index:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
 


 
 
ARXXANT   ARXXANT
 

 


Arxxant is an investigational drug, ruboxistaurin mesylate reduced the occurrence of vision loss in patients with diabetic retinopathy. Elli Lilly and Company is waiting for the approval of Arxxant for the treatment of Diabetic Retinopathy, the initial indication for ruboxistaurin from the United States Food & Drug Administration (FDA). The phase 3 clinical trails of Arxxant are completed.


Arxxant reduced the risk of vision loss in diabetics by nearly 41 percent, according to data from two Lilly-funded late-stage studies, which compared the experimental drug to a placebo. The three-year studies mainly focused on 813 patients, and found that declining vision occurred in 6.1 percent of patients taking Arxxant, also known as ruboxistaurin, compared to 10.2 percent in those taking placebo.

In this condition the vision loss cannot be corrected with the use of glasses, nor is it likely that any drug will restore the original vision, Arxxant medical director for Lilly said.

The findings that were announced at the American Diabetes Association's annual conference are important because retinopathy, or vision loss, affects 40 to 45 percent of all diabetics, according the National Institutes of Health. The potential patient pool is considerable because the ADA estimates that there are 20.8 million diabetics in America.

Diabetic retinopathy is a condition that leads to a progressive damage to the small blood vessels of the eye, and that can lead to vision loss and possible blindness. According to the World Health Organization and the American Diabetes Association estimates, DR is the leading cause of vision loss in adults of working age (20 to 65 years) in industrialized countries.

Enquiry Field Marked with asterisk (*) are mandatory
Name * Email *
State/Country
Comments *
 

 
 
Currently there are no comments or questions written by any user on "ARXXANT". You can be the First one to write one.
 
 
Obstatrix 100 , Zilauton , Multivitemins wc , Rinada bid , Giltus , Stres , Guaitusin ac , Oncor , Restfully slep , Vasanoid
Latest News About arxxant


Review of Top Drug
Stores to Buy Drugs

Generic Drugs

4Rx.com
XlPharmacy.com
Generic-Pharmacy.net
UsOnlineRX.net
V-Medical.com
ToPills.com

Brand Drugs

121Doc.com
AtlanticDrugs.com
SpeedyHealth.com
GetPharma.com
eDrugStore.md
OnlineClinic.co.uk
HealthExpress.co.uk
EuroClinix.net
drugsreport.co.uk is an independent news website reporting on various new and old drugs developed and marketed by its respective company. Nothing on this website is intended to infringe on any trademark nor any thing on website is intended as medical advice. The information provided here is for informational purposes only. Always consult a medical professional or a doctor with questions you may have regarding a medical condition.